{
  "meta": {
    "data_length": 1,
    "message": "Statement id stmt:hpra:aromasin:0:0 retrieved successfully",
    "request_url": "https://api.moalmanac.org/statements?statement_id=stmt%3Ahpra%3Aaromasin%3A0%3A0",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.002128,
    "timestamp_received": "2026-10-17T00:01:13.093340+00:00Z",
    "timestamp_returned": "2026-10-17T00:01:13.095468+00:00Z",
    "trace_id": "894b6674-59f0-485d-811f-a4ab2922232a"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://moalmanac.org",
    "last_updated": "2026-08-02"
  },
  "data": [
    {
      "id": "stmt:hpra:aromasin:0:0",
      "type": "Statement",
      "description": "The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized exemestane for the adjuvant treatment of patients who are postmenopausal women with hormone receptor-positive invasive early breast cancer (EBC) who have received 2 to 3 years of initial tamoxifen therapy.",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2024-11-10:0",
          "type": "Contribution",
          "description": "Adding HRPA approvals for use to database",
          "date": "2024-11-10",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:hpra:aromasin",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Aromasin (exemestane) [summary of product characteristics]. HPRA.",
          "title": null,
          "aliases": [],
          "description": "Pfizer Healthcare Ireland. Aromasin 25 mg coated tablets (Exemestane) [summary of product characteristics]. Health Products Regulatory Authority website. https://assets.hpra.ie/products/Human/23117/Licence_PA0822-111-001_09012025155108.pdf. Revised January 2025. Accessed May 25, 2025.",
          "urls": [
            "https://assets.hpra.ie/products/Human/23117/Licence_PA0822-111-001_09012025155108.pdf",
            "https://www.hpra.ie/find-a-medicine/for-human-use/authorised-medicines/details/23117"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:hpra",
                "type": "Agent",
                "agentType": "organization",
                "name": "Health Products Regulatory Authority",
                "description": "National register of authorized medicines in the Republic of Ireland."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Pfizer Healthcare Ireland",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Aromasin",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "exemestane",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": null,
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": null,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2022-06-10",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "direction": "supports",
      "proposition": {
        "id": "prop:vtxr:788",
        "type": "VariantTherapeuticResponseProposition",
        "predicate": "predictsSensitivityTo",
        "subjectVariant": {
          "type": "CategoricalVariant",
          "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition."
        },
        "conditionQualifier": {
          "id": "dis:ncit:C9245",
          "conceptType": "Disease",
          "name": "Invasive Breast Carcinoma",
          "mappings": [
            {
              "relation": "exactMatch",
              "coding": {
                "id": "coding:oncotree:BRCA",
                "code": "BRCA",
                "name": "Invasive Breast Carcinoma",
                "system": "https://oncotree.mskcc.org",
                "systemVersion": "oncotree_2025_10_03",
                "iris": [
                  "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=Invasive+Breast+Carcinoma+%28BRCA%29"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "solid_tumor",
              "value": true,
              "description": "Boolean value for if this tumor type is categorized as a solid tumor."
            }
          ],
          "primaryCoding": {
            "id": "coding:ncit:C9245",
            "code": "C9245",
            "name": "Invasive Breast Carcinoma",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "26.08e",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C9245"
            ]
          }
        },
        "objectTherapeutic": {
          "id": "tx:ncit:C1097",
          "conceptType": "Therapy",
          "name": "Exemestane",
          "mappings": [
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "coding:rxcui:258494",
                "code": "258494",
                "name": "exemestane",
                "system": "RxNorm",
                "systemVersion": "20250602",
                "iris": [
                  "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=258494"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "coding:omop:1398399",
                "code": "1398399",
                "name": "exemestane",
                "system": "OMOP",
                "systemVersion": "v20250827",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/1398399"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "therapy_strategy",
              "value": [
                "Aromatase inhibition"
              ],
              "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
              "name": "therapy_type",
              "value": "Hormone therapy",
              "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
          ],
          "primaryCoding": {
            "id": "coding:ncit:C1097",
            "code": "C1097",
            "name": "Exemestane",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "26.08e",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1097"
            ]
          }
        },
        "extensions": [
          {
            "name": "biomarkers",
            "value": [
              {
                "id": "bmkr.criterion:1",
                "present": true,
                "subject": {
                  "id": "bmkr:1",
                  "type": "CategoricalVariant",
                  "name": "ER positive",
                  "constraints": [],
                  "extensions": [
                    {
                      "name": "biomarker_type",
                      "value": "Protein expression"
                    },
                    {
                      "name": "marker",
                      "value": "Estrogen receptor (ER)"
                    },
                    {
                      "name": "unit",
                      "value": "status"
                    },
                    {
                      "name": "equality",
                      "value": "="
                    },
                    {
                      "name": "value",
                      "value": "Positive"
                    }
                  ]
                }
              }
            ],
            "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic."
          }
        ]
      },
      "strength": {
        "id": "str:ncit:C25425",
        "conceptType": "Evidence",
        "name": "Approval",
        "mappings": [],
        "primaryCoding": {
          "id": "coding:ncit:C25425",
          "code": "C25425",
          "name": "Approval",
          "system": "https://evsexplore.semantics.cancer.gov",
          "systemVersion": "26.08e",
          "iris": [
            "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425"
          ]
        }
      },
      "extensions": [
        {
          "name": "status",
          "value": "Active",
          "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db."
        },
        {
          "name": "indication",
          "value": {
            "id": "ind:hpra:aromasin:0",
            "type": "Indication",
            "description": "Aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer (EBC), following 2 - 3 years of initial adjuvant tamoxifen therapy.",
            "contributions": [
              {
                "id": "ctrb:vanallenlab:2024-11-10:0",
                "type": "Contribution",
                "description": "Adding HRPA approvals for use to database",
                "date": "2024-11-10",
                "contributor": {
                  "id": "agent:user:vanallenlab",
                  "type": "Agent",
                  "agentType": "contributor",
                  "name": "Van Allen lab",
                  "description": "Van Allen lab, Dana-Farber Cancer Institute"
                }
              }
            ],
            "reportedIn": [
              {
                "id": "doc:hpra:aromasin",
                "type": "Document",
                "documentType": "Regulatory approval",
                "name": "Aromasin (exemestane) [summary of product characteristics]. HPRA.",
                "title": null,
                "aliases": [],
                "description": "Pfizer Healthcare Ireland. Aromasin 25 mg coated tablets (Exemestane) [summary of product characteristics]. Health Products Regulatory Authority website. https://assets.hpra.ie/products/Human/23117/Licence_PA0822-111-001_09012025155108.pdf. Revised January 2025. Accessed May 25, 2025.",
                "urls": [
                  "https://assets.hpra.ie/products/Human/23117/Licence_PA0822-111-001_09012025155108.pdf",
                  "https://www.hpra.ie/find-a-medicine/for-human-use/authorised-medicines/details/23117"
                ],
                "doi": null,
                "pmid": null,
                "extensions": [
                  {
                    "name": "agent",
                    "value": {
                      "id": "agent:org:hpra",
                      "type": "Agent",
                      "agentType": "organization",
                      "name": "Health Products Regulatory Authority",
                      "description": "National register of authorized medicines in the Republic of Ireland."
                    },
                    "description": "The organization that published this document."
                  },
                  {
                    "name": "company",
                    "value": "Pfizer Healthcare Ireland",
                    "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
                  },
                  {
                    "name": "drug_name_brand",
                    "value": "Aromasin",
                    "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
                  },
                  {
                    "name": "drug_name_generic",
                    "value": "exemestane",
                    "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
                  },
                  {
                    "name": "first_publication_date",
                    "value": null,
                    "description": "The publication date for the initial version of this document."
                  },
                  {
                    "name": "identification_number",
                    "value": null,
                    "description": "Identification number used by the publishing organization."
                  },
                  {
                    "name": "publication_date",
                    "value": "2022-06-10",
                    "description": "The publication date for the document."
                  },
                  {
                    "name": "status",
                    "value": "Active",
                    "description": "Whether this document is Active or Deprecated within moalmanac-db."
                  }
                ]
              }
            ],
            "extensions": [
              {
                "name": "status",
                "value": "Approved",
                "description": "Current approval status."
              }
            ]
          },
          "description": "The underlying Indication supporting this Statement."
        }
      ]
    }
  ]
}